Depemokimab, an ultra-long-acting anti-IL-5 antibody, enables biannual dosing for severe eosinophilic asthma

Severe eosinophilic asthma (SEA) remains a significant global health burden, characterized by type 2 inflammation driven by eosinophils and often requiring frequent, burdensome treatments. Current biologic therapies targeting Interleukin-5 (IL-5), a key cytokine in eosinophil maturation and survival, have revolutionized care but typically require monthly or bi-monthly injections, impacting patient adherence and quality of life. There's a critical need for therapies that maintain efficacy with extended dosing intervals, reducing treatment burden and improving long-term patient management.

This review synthesizes findings from the Phase III SWIFT-1 and SWIFT-2 clinical trials evaluating depemokimab, a novel ultra-long-acting anti-IL-5 monoclonal antibody. Engineered with enhanced IL-5 binding affinity and Fc modifications, depemokimab was designed for prolonged systemic persistence, enabling a biannual (twice-yearly) administration schedule. The primary endpoint across these trials focused on reductions in annualized asthma exacerbations, comparing its efficacy and safety profile against established anti-IL-5 agents in patients with severe eosinophilic asthma.

Phase III SWIFT-1 and SWIFT-2 trials demonstrated significant reductions in annualized asthma exacerbations, indicating a robust clinical benefit for patients with severe eosinophilic asthma. The efficacy of depemokimab was found to be comparable to established anti-IL-5 agents, suggesting it offers a similar level of disease control through sustained eosinophil suppression.

A favorable safety profile was observed across both trials, aligning with the known tolerability of anti-IL-5 therapies. However, the benefits in lung function, symptom control, and quality of life were less consistent, highlighting the complex interplay between eosinophilic inflammation and the broader manifestations of the disease. This suggests that while IL-5 inhibition effectively reduces exacerbations, other pathways may contribute to these less responsive aspects of the disease.